<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04131621</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-8WY</org_study_id>
    <nct_id>NCT04131621</nct_id>
  </id_info>
  <brief_title>Nivolumab/Ipilimumab in Second Line CUP-syndrome</brief_title>
  <acronym>CheCUP</acronym>
  <official_title>A Phase II, Open-label, Non-randomized, Multi-center Study Evaluating the Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Cancer of Unknown Primary Site Who Are Relapsed After or Refractory to Platinum-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of nivolumab plus ipilimumab in subjects with high vs.&#xD;
      Intermediate/low TMB poor-prognosis CUP (non-specific subset) who are relapsed or refractory&#xD;
      to platinum-based first-line chemotherapy.&#xD;
&#xD;
      To evaluate the efficacy of nivolumab plus ipilimumab in subjects with poor-prognosis CUP&#xD;
      (non-specific subset) who are relapsed or refractory to platinum-based first-line&#xD;
      chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 months</time_frame>
    <description>Months</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Cancer of Unknown Primary Site</condition>
  <arm_group>
    <arm_group_label>Nivolumab/Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab/Ipilimumab</intervention_name>
    <description>Immune checkpoint inhibitor combination</description>
    <arm_group_label>Nivolumab/Ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
          -  Able and willing to comply with the study protocol&#xD;
&#xD;
          -  Age ≥ 18 years at time of signing Informed Consent Form&#xD;
&#xD;
          -  Histologically-confirmed disseminated or advanced unresectable CUP diagnosed according&#xD;
             the criteria defined in the 2015 ESMO Clinical Practice Guidelines for CUP. Acceptable&#xD;
             disease histology includes:&#xD;
&#xD;
               -  Adenocarcinoma of unknown primary site (ACUP)&#xD;
&#xD;
               -  Poorly differentiated adenocarcinoma of unknown primary site&#xD;
&#xD;
               -  Poorly differentiated carcinoma of unknown primary site&#xD;
&#xD;
               -  Squamous cell carcinoma of unknown primary site (SCUP)&#xD;
&#xD;
          -  At least one lesion that is measurable according to RECIST v1.1&#xD;
&#xD;
          -  Availability of a tumor FFPE block either fresh or archival if obtained ≤ 6 months at&#xD;
             Screening that is sufficient for generation of a TruSight Oncology 500 (TSO500) panel&#xD;
             at the central reference pathology laboratory&#xD;
&#xD;
          -  Availability of test reports confirming local CUP diagnosis. If test reports&#xD;
             confirming local CUP diagnosis are not available, an FFPE block must be submitted that&#xD;
             is sufficient to allow for central confirmation of CUP diagnosis&#xD;
&#xD;
          -  Disease relapse or progression after at least three cycles of a platinum-based&#xD;
             standard chemotherapy. There is no upper limit of prior treatments received.&#xD;
&#xD;
          -  ECOG performance status of 0 - 2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Eligible for immune checkpoint inhibitor&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  For women of childbearing potential and men capable of reproduction: agreement to&#xD;
             remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods&#xD;
             with a failure rate of &lt; 1% per year during the treatment period and for at least 5&#xD;
             months for women and 7 months for men, respectively after the last dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Recovery from significant toxicity from platinum-doublet therapy to Grade ≤ 1, except&#xD;
             for alopecia and for neurosensory toxicity, which must be ≤ 2&#xD;
&#xD;
          -  Recovery from active infections requiring intravenous antibiotics, with antibiotic&#xD;
             therapy ceased for ≥ 7 days prior to planned start of therapy&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Subjects with any of the specific non-CUP neoplasms identified in the ESMO CUP&#xD;
             guidelines, including:&#xD;
&#xD;
               -  Non-epithelial cancer&#xD;
&#xD;
               -  Extragonadal germ-cell tumor&#xD;
&#xD;
          -  Subjects belonging to any of the following subsets of CUP with favorable prognoses:&#xD;
&#xD;
               -  Poorly differentiated carcinoma with midline distribution&#xD;
&#xD;
               -  Women with papillary adenocarcinoma of the peritoneal cavity&#xD;
&#xD;
               -  Women with adenocarcinoma involving only the axillary lymph nodes&#xD;
&#xD;
               -  Squamous cell carcinoma restricted to cervical lymph nodes&#xD;
&#xD;
               -  Poorly and well differentiated neuroendocrine tumors&#xD;
&#xD;
               -  Men with blastic bone metastases and elevated PSA&#xD;
&#xD;
               -  Subjects with a single, small tumor potentially resectable and/or amenable to&#xD;
                  radiotherapy with curative intent&#xD;
&#xD;
               -  Colon cancer-type CUP&#xD;
&#xD;
          -  Known presence of brain or spinal cord metastasis (including metastases that have been&#xD;
             irradiated), as determined by CT or magnetic resonance imaging (MRI) evaluation during&#xD;
             screening&#xD;
&#xD;
          -  History or known presence of leptomeningeal disease&#xD;
&#xD;
          -  Uncontrolled or symptomatic hypercalcemia (serum calcium ≥ 2.9mmol/L)&#xD;
&#xD;
          -  Known clinically significant history of liver disease consistent with Child-Pugh Class&#xD;
             B or C, including active viral or other hepatitis, current alcohol abuse, or cirrhosis&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Positive for hepatitis C virus (HCV) infection at screening&#xD;
&#xD;
          -  Positive for hepatitis B surface antigen (HBsAg) at screening&#xD;
&#xD;
          -  Active tuberculosis at Screening&#xD;
&#xD;
          -  Significant cardiovascular disease (such as New York Heart Association Class II or&#xD;
             greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3&#xD;
             months prior to initiation of study treatment, unstable arrhythmia (including active&#xD;
             ventricular arrhythmia requiring medication), or unstable angina&#xD;
&#xD;
          -  Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation&#xD;
             of study treatment, or anticipation of need for a major surgical procedure during the&#xD;
             study&#xD;
&#xD;
          -  History of malignancy other than CUP within 5 years prior to screening, with the&#xD;
             exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year&#xD;
             OS rate &gt; 90%), such as adequately treated carcinoma in situ of the cervix, non&#xD;
             melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or stage&#xD;
             I uterine cancer&#xD;
&#xD;
          -  Prior allogeneic stem cell or solid organ transplantation&#xD;
&#xD;
          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding that contraindicates the use of an investigational drug, may affect&#xD;
             the interpretation of the results, or may render the patient at high risk from&#xD;
             treatment complications&#xD;
&#xD;
          -  Treatment with investigational therapy within 28 days prior to initiation of study&#xD;
             treatment&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any component of the immunotherapy, including&#xD;
             history of severe allergic anaphylactic reactions to chimeric or humanized antibodies&#xD;
             or fusion proteins and to Chinese hamster ovary cell products or other recombinant&#xD;
             human or humanized antibodies for nivolumab and ipilimumab.&#xD;
&#xD;
          -  Subjects with an active, known or suspected autoimmune disease, including, but not&#xD;
             limited to, myasthenia gravis, myositis, autoimmune hepatitis, myocarditis, systemic&#xD;
             lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease,&#xD;
             antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome,&#xD;
             Guillain-Barré syndrome, or multiple sclerosis. Subjects with type I diabetes&#xD;
             mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as&#xD;
             vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not&#xD;
             expected to recur in the absence of an external trigger are permitted to enroll.&#xD;
&#xD;
          -  Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10 mg daily prednisone equivalents, or other immuno-suppressive medications within 14&#xD;
             days of study treatment. Inhaled or topical steroids and adrenal replacement doses &gt;&#xD;
             10 mg daily prednisone equivalents for adults, or &gt; 0.25 mg/kg daily prednisone&#xD;
             equivalent for adolescents are permitted, in the absence of active autoimmune disease.&#xD;
&#xD;
          -  Subjects who received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2,&#xD;
             anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically&#xD;
             targeting T-cell co-stimulation or checkpoint pathways&#xD;
&#xD;
          -  All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue&#xD;
             must have resolved to Grade 1 (NCI CTCAE version 5) or baseline before administration&#xD;
             of study drug. Subjects with toxicities attributed to prior anti-cancer therapy which&#xD;
             are not expected to resolve and result in long lasting sequelae, such as neuropathy&#xD;
             after platinum based therapy, are permitted to enroll.&#xD;
&#xD;
          -  Treatment with any chemotherapy, radiation therapy, biologics for cancer, or&#xD;
             investigational therapy within 28 days of first administration of study treatment&#xD;
             (subjects with prior cytotoxic or investigational products &lt; 4 weeks prior to&#xD;
             treatment initiation might be eligible after discussion between investigator and&#xD;
             sponsor, if toxicities from the prior treatment have been resolved to Grade 1 (NCI&#xD;
             CTCAE version 5).&#xD;
&#xD;
          -  Subjects must not have received a live / attenuated vaccine within 30 days of first&#xD;
             treatment.&#xD;
&#xD;
          -  Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment&#xD;
             or within 5 months after the last dose of study treatment or intention of fathering a&#xD;
             child within 7 months after the last dose of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alwin Kraemer</last_name>
    <phone>0049622142</phone>
    <phone_ext>1440</phone_ext>
    <email>a.kraemer@dkfz.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alwin Kraemer</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Alwin Kraemer</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

